The stock of Bicycle Therapeutics Plc ADR (BCYC) has seen a 6.58% increase in the past week, with a -2.32% drop in the past month, and a 35.17% flourish in the past quarter. The volatility ratio for the week is 4.44%, and the volatility levels for the past 30 days are at 4.68% for BCYC. The simple moving average for the past 20 days is 1.53% for BCYC’s stock, with a 17.70% simple moving average for the past 200 days.
Is It Worth Investing in Bicycle Therapeutics Plc ADR (NASDAQ: BCYC) Right Now?
Additionally, the 36-month beta value for BCYC is 0.92. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for BCYC is 41.93M and currently, short sellers hold a 6.06% ratio of that float. The average trading volume of BCYC on April 18, 2024 was 390.88K shares.
BCYC) stock’s latest price update
Bicycle Therapeutics Plc ADR (NASDAQ: BCYC) has experienced a rise in its stock price by 9.90 compared to its previous closing price of 21.82. However, the company has seen a gain of 6.58% in its stock price over the last five trading days. Seeking Alpha reported 2024-03-25 that M&A activity in the biotech/biopharma sector is expected to remain active due to significant cash on Big Pharma’s balance sheets, key patent expirations, and declining revenue from Covid related products. The oncology space continues to be a hot and active area for deal volume, with global sales projected to reach $375 billion by 2027. Today, we profile two smaller oncology names that appear to be logical acquisitions for larger concerns that want to expand their oncology footprints.
Analysts’ Opinion of BCYC
Barclays gave a rating of “Overweight” to BCYC, setting the target price at $30 in the report published on July 28th of the previous year.
BCYC Trading at 3.13% from the 50-Day Moving Average
After a stumble in the market that brought BCYC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -17.05% of loss for the given period.
Volatility was left at 4.68%, however, over the last 30 days, the volatility rate increased by 4.44%, as shares sank -6.77% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +39.38% upper at present.
During the last 5 trading sessions, BCYC rose by +6.11%, which changed the moving average for the period of 200-days by -3.92% in comparison to the 20-day moving average, which settled at $23.53. In addition, Bicycle Therapeutics Plc ADR saw 32.63% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BCYC starting from Hannay Michael Charles Ferguso, who sale 257 shares at the price of $22.49 back on Apr 11 ’24. After this action, Hannay Michael Charles Ferguso now owns 22,891 shares of Bicycle Therapeutics Plc ADR, valued at $5,780 using the latest closing price.
Lee Kevin, the CHIEF EXECUTIVE OFFICER of Bicycle Therapeutics Plc ADR, sale 3,158 shares at $23.81 during a trade that took place back on Apr 03 ’24, which means that Lee Kevin is holding 387,270 shares at $75,192 based on the most recent closing price.
Stock Fundamentals for BCYC
Current profitability levels for the company are sitting at:
- -7.04 for the present operating margin
- 0.76 for the gross margin
The net margin for Bicycle Therapeutics Plc ADR stands at -6.7. The total capital return value is set at -0.36. Equity return is now at value -56.50, with -36.04 for asset returns.
Based on Bicycle Therapeutics Plc ADR (BCYC), the company’s capital structure generated 0.11 points at debt to capital in total, while cash flow to debt ratio is standing at -1.35. The debt to equity ratio resting at 0.12. The interest coverage ratio of the stock is -58.21.
Currently, EBITDA for the company is -168.8 million with net debt to EBITDA at 2.82. When we switch over and look at the enterprise to sales, we see a ratio of 19.81. The receivables turnover for the company is 1.12for trailing twelve months and the total asset turnover is 0.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.08.
Conclusion
In conclusion, Bicycle Therapeutics Plc ADR (BCYC) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
